Alnylam receives approval in europe for amvuttra® (vutrisiran) for the treatment of hereditary transthyretin-mediated (hattr) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced that the european commission (ec) has granted marketing authorization for amvuttra® (vutrisiran), an rnai therapeutic for the treatment of hereditary transthyretin-mediated (hattr) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy. the ec approval is based on positive 18-month results from the helios-a phase 3 study, where amvuttra significan
ALNY Ratings Summary
ALNY Quant Ranking